Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

• Published in: Journal for immunotherapy of cancer Vol. 7; no. 1; pp. 322 - 10
• Main Authors: Zhang, Xuanye, Zhou, Yixin, Chen, Chen, Fang, Wenfeng, Cai, Xiuyu, Zhang, Xiaoshi, Zhao, Ming, Zhang, Bei, Jiang, Wenqi, Lin, Zuan, Ma, Yuxiang, Yang, Yunpeng, Huang, Yan, Zhao, Hongyun, Xu, Ruihua, Hong, Shaodong, Zhang, Li
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 21.11.2019; BioMed Central Ltd; BMJ Publishing Group LTD; BioMed Central; BMJ Publishing Group
• Subjects: Alcoholism; Antibodies; Antigens; Antiviral agents; Apoptosis; Biochemistry; Cancer; Cancer patients; Cancer therapies; Care and treatment; Cell death; Checkpoint; Chemotherapy; Clinical trials; Clinical/Translational Cancer Immunotherapy; Cytotoxicity; Disease prevention; DNA; Health aspects; Hepatitis A; Hepatitis B; Hepatitis B virus; Hepatitis C; Hepatitis delta virus; HIV; Human immunodeficiency virus; Immunosuppressive agents; Immunotherapy; Infection; Infections; Ligands; Liver cancer; Liver cirrhosis; Medical research; Patients; PD-1; PD-L1; Prophylaxis; Reactivation; Regulatory approval; Research Article; Safety; Steroids; Viruses; United States > US; Checkpoint; Reactivation; Immunotherapy; PD-L1; Hepatitis B virus; Safety; PD-1; Cancer

BackgroundHepatitis B virus (HBV) reactivation is a serious complication in patients with cancers and HBV infection undergoing immunosuppressant treatment or chemotherapy. However, the safety of anti-programmed cell death (PD) -1 and anti-programmed cell death-ligand 1 (PD-L1) therapy in these patie...